(600521)"ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD."Report for Q3 2026
Filed with SSE · Stock code 600521 · · 17 pages · Chinese
Summary by 6ix AI
The report highlights significant increases in revenue and profit compared to the same period last year, indicating strong business growth. The company assures the accuracy and completeness of the report's content, which has not been audited. Key financial metrics include total revenue and net profit attributed to shareholders, reflecting the company's operational success.
Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries
Zhejiang Huahai Pharmaceutical Co., Ltd. on 6ix
Earlier from Zhejiang Huahai Pharmaceutical
- (600521)"ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD."Announcement on Redemption at Maturity and Delisting of "HUAHAI Convertible Bonds"
- (600521)"ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD."Announcement on Obtaining Drug Registration Certificate
- (600521)"ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD."Announcement on Resolutions of the 17th Extraordinary Meeting of the 9th Board of Directors
- (600521)"ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD."Announcement on Capital Increase and Share Expansion of Controlled Subsidiary for Introduction of Investors
- (600521)"ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD."Announcement on Resolutions of the 16th Extraordinary Meeting of the 9th Board of Directors
Later from Zhejiang Huahai Pharmaceutical
- (600521)"ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD."Announcement on Obtaining Approval for Drug Clinical Trials by Subsidiary
- (600521)"ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD."Announcement on Results of Redemption at Maturity of "HUAHAI Convertible Bonds" and Share Changes
- (600521)"ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD."Announcement on Progress in Providing Guarantee for Subsidiary
Follow Zhejiang Huahai Pharmaceutical into a list and get an email when it puts out news.
Follow Zhejiang Huahai Pharmaceutical